These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20655673)

  • 1. The incretin pathway as a new therapeutic target for obesity.
    Barber TM; Begbie H; Levy J
    Maturitas; 2010 Nov; 67(3):197-202. PubMed ID: 20655673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuro-modulation and bariatric surgery for type 2 diabetes mellitus.
    Spector D; Shikora S
    Int J Clin Pract Suppl; 2010 Feb; (166):53-8. PubMed ID: 20377665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
    Barnett AH
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
    Ranganath LR
    J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.
    Sesti G
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():4-10. PubMed ID: 19878256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of incretin on diabetes mellitus.
    Sanusi H
    Acta Med Indones; 2009 Oct; 41(4):205-12. PubMed ID: 20737753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ; Ernest P
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
    Knop FK; Holst JJ; Vilsbøll T
    IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological therapies for obesity.
    Kaplan LM
    Gastroenterol Clin North Am; 2005 Mar; 34(1):91-104. PubMed ID: 15823441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
    Pi-Sunyer FX
    Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin based therapies for type 2 diabetes mellitus.
    Ghosh S; Collier A; Elhadd T; Malik I
    J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabesity: therapeutic options.
    Colagiuri S
    Diabetes Obes Metab; 2010 Jun; 12(6):463-73. PubMed ID: 20518802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF; Wauters MA; De Leeuw IH
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.